Irbesartan 150mg Dosage for Hypertension
The recommended starting dose of irbesartan for hypertension is 150 mg once daily, which can be increased to a maximum of 300 mg once daily as needed to control blood pressure.
Dosing Algorithm
According to the FDA label, the standard approach is 1:
- Initial dose: 150 mg once daily
- Titration: Increase to 300 mg once daily if blood pressure control is inadequate
- Administration: Can be taken with or without food, once daily dosing provides 24-hour coverage
Special Circumstances
Volume or salt depletion: Start with 75 mg once daily in patients who are volume-depleted (e.g., those on aggressive diuretic therapy or hemodialysis) to avoid hypotension 1.
Evidence Supporting This Dosing
The 150 mg starting dose is supported by robust clinical trial data showing 1:
- Blood pressure reduction: 150 mg once daily produces clinically significant decreases of approximately 8-10/5-6 mmHg (systolic/diastolic) at trough (24 hours post-dose)
- 300 mg dose: Provides slightly greater reduction of 8-12/5-8 mmHg
- No additional benefit: Doses above 300 mg showed no further increase in antihypertensive effect
- Onset of action: Effect is apparent after the first dose, with near-maximal effect achieved by 2 weeks
Guideline Context
Current hypertension guidelines support ARBs like irbesartan as first-line agents 2:
- The 2017 ACC/AHA guidelines list irbesartan with a usual dose range of 150-300 mg once daily 2
- ARBs are recommended as one of four first-line drug classes (along with thiazide diuretics, ACE inhibitors, and calcium channel blockers) 3
Treatment Intensity Based on Hypertension Stage
Stage 1 hypertension (130-139/80-89 mmHg): Monotherapy with 150 mg is reasonable, with dose titration as needed 4
Stage 2 hypertension (≥140/90 mmHg): Consider initiating combination therapy with two agents from different classes 2, 5. If using irbesartan, start at 150 mg and add a thiazide diuretic or calcium channel blocker rather than increasing to 300 mg monotherapy initially.
Combination Therapy Considerations
When monotherapy at 150 mg is insufficient 1, 6:
- Add hydrochlorothiazide: Produces additive blood pressure reduction
- Add calcium channel blocker: The combination of irbesartan 300 mg/amlodipine 5 mg produces superior blood pressure lowering compared to irbesartan 300 mg alone 7
- Avoid: Do not combine with ACE inhibitors or direct renin inhibitors due to increased risk of hyperkalemia and acute kidney injury 2, 4
Clinical Monitoring
- Initial follow-up: Reassess blood pressure within 1 month after starting therapy 2
- Target blood pressure: <130/80 mmHg for most patients per current guidelines 2
- Dose adjustment: If blood pressure remains uncontrolled at 4 weeks on 150 mg, increase to 300 mg or add a second agent
Safety Profile
Irbesartan 150-300 mg once daily demonstrates 8, 9, 10:
- Adverse event rates similar to placebo
- No dose-related increase in side effects
- Lower incidence of cough compared to ACE inhibitors
- No ankle edema (unlike calcium channel blockers)
- Monitor for hyperkalemia, especially in patients with chronic kidney disease or those on potassium supplements